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The aim of the study was to establish a reproducible murine model for latent tuberculosis. We propose an operational
definition of latent murine tuberculosis as a stable Mycobacterium tuberculosis count in lungs and spleens without clinical
signs or obvious histopathological changes in the lungs over a long period of time and without spontaneous reactivation of
disease. B6D2F1Bom mice were inoculated with a wide range of Mycobacterium tuberculosis doses intraperitoneally or
intravenously and followed for a long period to determine suitable conditions to produce latent infection. No anti-tuberculosis
drug treatment was used. Microbiological and histopathological studies were carried out. Corticosterone challenge was used
to reactivate the latent infection. Mice infected with 4104 and 4105 bacilli i.p. were followed up to 107 weeks without
spontaneous reactivation. The present model is discussed in comparison with previous latent tuberculosis mouse models as well
as the possible mechanisms of shift to stationary phase from multiplying bacilli.
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INTRODUCTION
With the challenge of the global tuberculosis situation, it is
increasingly recognized that current tuberculosis (TB) con-
trol strategies suffer from severe shortcomings. The only
available vaccine, Bacille Calmette-Guerin (BCG), has a
substantial impact on severe forms of childhood TB (1–3).
However, it seems neither to prevent the establishment of
latent TB infection nor the reactivation of a latent infec-
tion. Chemotherapy also has a limited impact on transmis-
sion due to late diagnosis, low compliance (4, 5) and the
emergence of drug resistance (6).
The reactivation of clinical TB from latent infection has
been difficult to characterize except among elderly people
living in countries without ongoing transmission of TB
(7–9). Recently a restriction fragment length polymorphism
(RFLP) method was applied to study the transmission of
TB within groups at high risk of infection (10–15). Some of
these studies indicated that recent transmission accounts for
approximately one-third of the incidence in San Francisco
(14) and 26% (13) to 28% (15) (after subtraction of possible
index cases) of incidence in New York City. A higher
proportion of clustered strains was seen among TB patients
co-infected with Human Immunodeficiency Virus (HIV),
poor TB drug compliants, low wages earners, people previ-
ously treated for TB, and those living under crowded
conditions. This seems to support the assumption that
recent transmission contributes a substantial portion of new
TB cases in these groups (15, 16) and also in endemic areas
(17). However, the studies described above (13–15) showed
that most foreign-born TB patients did not carry strains
identified in those in close proximity, implying that clinical
TB in these patients was most probably due to reactivation
of an infection acquired before migration. Today almost
one-third of the world population is infected with My-
cobacterium tuberculosis (Mtb) (18), constituting a large
reservoir for reactivation of latent TB. In the pre-HIV
period, an individual infected with Mtb had approximately
a 10% lifetime risk of developing clinical TB (19). Reacti-
vated TB appears as pulmonary with cavitary lesions (spu-
tum positive) (20–22), and is therefore the main source of
TB transmission in society (19, 23, 24). However, there is
no effective preventive measure available.
The basic problem we face is an almost complete lack of
knowledge concerning the biology of bacillary dormancy
and the relationship between dormant bacilli and host
immunity. Characterization of the metabolism and antigens
(Ag) expression of Mtb during dormancy could be instru-
mental for the development of new anti-TB drugs and
immune interventions effective against latent infection.
There is thus an urgent need to establish simple, reliable
and effective animal model for latent TB.
A chronic murine TB model has been described previ-
ously (25–31). The differences between our model and the
previous models are that (1) it mimics the natural course of
latent infection by avoiding the use of anti-TB drugs. (2)
We can follow up infected healthy mice for more than 100
weeks post-infection without seeing spontaneous reactiva-
tion of disease. Thus this model mimics the natural latency
in humans where the bacilli may remain dormant for many
years before being reactivated. (3) Relatively high numbers
of bacilli in organs of mice in our model offer an opportu-
nity to study the nature of dormant bacilli and immune
responses of the mice in the latent period.
The work described here aims at developing a simple and
reproducible mouse model for studies of latent tuberculosis.
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© 1998 Scandinavian University Press. ISSN 0036-5548
Scand J Infect Dis 30S. Phyu et al.60
Table I. Experimental design for Mtb infected mice
Experiment 2Experiment 1
II III IVGroups of mice I II III IV VI
6 6 4 30 304 30 30 30No. of mice
105 105Dose of infection 108 4101 4102 4103 4104 4105103
i.v. i.p. i.p. i.p. i.p. i.p. i.p. i.p.i.v.Route of infection
4101–4103 low-dose infection, 4104–4105moderate-dose infection, 1108high-dose infection.
MATERIALS AND METHODS
Mice
B6D2F1Bom (C57BL:6JBomDBA:2JBom) mice were pur-
chased from Bomholtga˚rd Breeding and Research Centre Ltd,
Denmark. This centre follows the FELASA (Federation of Eu-
ropean Laboratory Animal Science Association) recommendations
for health control of laboratory animals. The animals were accli-
matized for at least 7 d before being included in the experiments.
All mice were aged about 17 weeks when they were used in
experiments. The average life-span of these mice is 975 d (32).
Animals were given standard mouse diet (RM1, SDS, Witham,
UK) and water ad libitum. They were kept in MAKIII macorolon
cages. The cages were kept in negative pressure plastic film isola-
tors (Plastic Film Industries, UK). The isolators were supplied with
temperature (22°C91°C) and humidity (50%910% R.H) con-
trolled air. The room lighting was set at 14:10 light:dark. The
experiments were performed with the permission of the Norwegian
Experimental Animal Board. Norwegian Law has been harmo-
nized with the European Convention on the Protection of Experi-
mental Animals.
Mycobacteria
All experiments were conducted with the H37Rv strain of Mtb.
The mycobacteria were first cultured on Lowenstein-Jensen media
for 10 weeks.
Preparation of inocula
Stock inocula were prepared by subculturing colonies in Middle-
brook 7H9 liquid supplemented by Middlebrook ADC (Difco
laboratories, Detroit, MI) (10: 1) and 0.05% Tween-80. The stock
culture was incubated at 37°C for 10 d and shaken briefly on
alternate days. Small aliquots of the stock bacillary suspension
were maintained at 70°C. The desired number of bacilli for
inoculation was prepared from the stock suspension after diluting
with phosphate buffered saline (PBS). The bacillary suspension for
inoculation was sonicated for 5 seconds in a water bath sonicator
(Gen-probe®, HF-frequency– 35kHz, Type-T460:H, Germany) be-
fore use.
Assessment of 6iability of stock culture by colony forming units
(CFU)
The stock culture was sonicated for 30 s in the bath sonicator. It
was then ten-fold serially diluted with medium and plated onto
Middlebrook 7H10. This medium was prepared by mixing agar
base Middlebrook 7H10 (Difco, Detroit Laboratories, MI, USA)
with Middlebrook OADC (Gibco, Life Technologies Ltd., Scot-
land). The inoculated plates were incubated at 37°C, in a CO2 (5%)
incubator. CFU were counted twice weekly after the appearance of
pinpoint size colonies.
Experimental design, routes and doses of infection
Two separate experiments were performed to know which route
and dose were suitable for establishing chronic infection. In the
first experiment Mtb was given in different doses intraperitoneally
(i.p.) or intravenouslly (i.v.) to four groups of mice (Table I). A
total of 20 mice were used for this experiment. This experiment was
terminated at week 15 and 21 post-infection (Fig. 1).
In the second experiment, different doses of infection were given
to 5 groups of mice i.p. (Table I). A total of 163 mice were used in
this experiment. Of these, 150 mice were infected and 13 were not.
Five uninfected mice served as controls for growth and age and
were kept in a separate isolator. The 8 remaining uninfected mice
were housed with the infected groups as sentinel controls to check
for transmission of infection and environmental conditions in the
cages. No cross-infection was observed. The time schedule for
sacrificing the mice in this experiment is shown in Fig. 4. The
experiment was terminated at week 77 post-infection for corticos-
terone-challenged mice, whereas unchallenged mice were still alive
until 115 weeks after infection.
The mice were given a range of inoculum between 4101 and
1108 bacilli in 0.2 ml PBS. Doses between 4101 and 4103
were designated ‘‘low-dose’’, 4104– 4105 ‘‘moderate-dose’’
and 1108 ‘‘high-dose’’ inocula.
Corticosterone challenge
By week 53 of infection, the CFU in the organs of infected mice
without signs of disease had remained stable for about 12 weeks
(see results). At week 53, half of the mice in the low- and
moderate-dose groups were given oral corticosterone (Sigma
Chemical, St Louis, MO, USA). The remaining mice were left as
controls. Corticosterone was dissolved in ethanol and then diluted
to a final concentration of 267 mg:ml in 1% ethanol and 0.5%
saline. Mice were given this solution in their drinking water. Mice
in each group drank from the same bottle. On average, one mouse
drank about 1.07 mg of corticosterone per day. The corticosterone
challenge started at about 25% of this dose. It was then doubled
after week 10, and increased to the final dose 13 weeks after the
start of corticosterone treatment.
Har6esting of organs
At the time of sacrifice mice were anaesthetized with 0.06 ml of (1:
1) mixture of Diazepam (Vival™, AL, Norway) and Fentanyl
citrate plus Fluanisone (Hypnorm™, Janssen Pharmaceutical Ltd,
UK) subcutaneously. After exsanguination by intracardiac punc-
ture, lungs, liver, spleen and femoral bone marrow were removed
under aseptic conditions.
Preparing of tissues and processing of specimens
Histopathology. About one third of each organ was fixed in
buffered formalin and embedded in paraffin for study of histo-
pathology. Sections approximately 5 mm thick were prepared and
stained with haematoxylin and eosin (H&E). For detection of Mtb
in the tissue specimens, an immunohistochemical method (33, 34)
was chosen owing to the results obtained during the first parts of
the experiment. Acid-fast staining gave a non-specific background
staining in the tissue of these mice. It was not possible to de-stain
carbol fuchsin with acid alcohol in mouse tissues. Different batches
of reagents, dilutions and staining procedures were used without
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achieving a reduction of the unspecified staining. The histochemi-
cal method proved more sensitive than acid-fast staining on the
positive human controls. Immunohistochemical staining was per-
formed by using anti-BCG antibodies (Ab). For retrieval of Ag,
sections were treated with 0.1% trypsin at 37°C for 20 min and
microwaved at 750 W for 5 min. Endogenous peroxidase activity
was blocked with 0.3% H2O2 for 5 min. In order to reduce
endogenous biotin staining, lung sections were pre-treated with
avidin and biotin blocking solution (Vector Laboratories,
Burlingame, USA, Cat. no. SP-2001). Sections were incubated with
avidin solution for 15 min, followed by a brief rinse with Tris
phosphate buffered saline (TBS), and incubation with biotin-block-
ing solution for 15 min. Incubation was carried out with swine
serum for 15 min. Sections were incubated overnight with rabbit
polyclonal anti-BCG Ab (Dako A:S, Denmark, code no. B124)
(dilution 1: 25 000) and by biotin-labelled swine anti-rabbit im-
munoglobulin serum (Dako A:S, Denmark, code no.E-353) (dilu-
tion 1: 400) for 30 min followed by 30 min with
avidin–biotin–peroxidase complex (ABC) (Dako A:S, Denmark,
code no.K0355). Location of Ag was visualized by H2O2 and
3-amino-9-ethylcarbazol containing buffer for 15 min. Sections
were washed in TBS for 5 min between each incubation. Slides
were slightly counterstained with Mayer’s haematoxylin, washed in
running tap water for 5 min and mounted with Immunomount
(polyvinyl alcohol resinglycerol). Human lung tissue with active
TB was used as a positive control and TBS was used instead of
primary Ab as a negative control.
Bacillary counts. One third of each organ was homogenized with
PBS in sterile glass homogenizers (Bellco, Vineland, NJ, USA).
Ten-fold serially diluted 50 ml tissue homogenates were plated on
Middlebrook 7H10 medium. The number of Mtb CFU per organ
was calculated and expressed as log10 per organ. The lowest
detectable CFU number in this study was about 200 CFU for
lungs and liver and 100 CFU for spleen. When the homogenates of
organs from corticosterone-treated mice were cultured, the medium
was supplemented with antibiotic and anti-fungal drugs (Carbeni-
cillin 100 mg:ml, Trimethoprim 15 mg:ml, Amphotericin B 10 mg:ml
& Polymyxin B 200U:ml). The culture plates were sealed with
adhesive tape and incubated at 37°C, in a CO2 (5%) incubator for
at least 3 weeks followed by incubation at 37°C in air. The reading
was discontinued when the count was stable for 3 weeks. Inocu-
lated culture plates processed from mice in the latent stage should
be kept for at least 4 months after inoculation. The reason for this
will be discussed in the discussion.
RESULTS
Route and dose related 6ariation in the clinical outcome of
Mtb infection
Mice given the moderate dose of 1105 CFU:mouse
given i.v. or a high dose of 1108 CFU:mouse given i.p.
(Group A), developed clinical disease. Mice given low
doses of Mtb either by the i.v or i.p. route and those
given the moderate-doses of Mtb by the i.p. route (Group
B), remained clinically healthy until challenged with corti-
costerone.
Clinical disease
Clinical signs of disease appeared by the 7th week after
infection in mice from Group A. Mice became less active,
lost weight, there was excessive licking and scratching
(performed abnormal groaning), they had hunched backs,
shallow and rapid respiration and secretions from eyes
and nose.
Bacillary counts in lungs and livers of high-dose i.p.
infected mice were approximately 1.5 log10 and 3 log10,
respectively, higher at the 8th week compared to the 4th
week of infection. However, bacillary counts in the spleens
at the 8th week was B0.5 log10 lower than at the 4th week
post-infection (Fig. 1A). A few bacilli were detected in bone
marrow and blood of sick mice from this group. A similar
growth pattern was found in the lungs of moderate-dose
Mtb i.v. infected mice (Fig. 1B). Bacillary growth was found
in the blood of sick mice from this group. The high-dose i.p.
infected mice experiment was terminated at the 15th week
post-infection due to disease and mortality of the mice,
while moderate-dose i.v. infected mice survived until the 21st
week of infection. At the 15th and 21st weeks of infection,
although the clinical signs of disease were getting worse, the
CFU in organs of these mice were decreasing gradually or
remained stable compared to the counts at the 8th week
post-infection (Fig. 1A, B).
When a moderate-dose of bacilli was given by i.v. route,
pinpoint greyish-black nodules were visible in the lungs 4
weeks after infection. Microscopically however, a focal
inflammatory cell infiltrate (granuloma) was detectable at
24 h post-infection in one of the infected mice. The cellular
composition of the granuloma showed a mixture of poly-
morphonuclear leukocytes (PMN), large macrophages with
pale cytoplasm and big weakly stained nuclei (histiocytes)
and few lymphocytes (Fig. 2A, B). After 4 weeks of infec-
tion the number of granulomas increased. The granulomas
consisted of a mixture of histiocytes and lymphocytes with
very few PMN (Fig. 2D, E). At 21 weeks of infection the
Fig. 1. CFU in organs of Mtb infected mice (experiment 1): (A)
i.p. high dose; (B) i.v. moderate dose; (C) i.p. moderate doses; and
(D) i.v. low doses infected mice. (d) 4 weeks, () 8 weeks, (
) 21
weeks post-infection for (B) and 15 weeks post-infection for the
others. CoContaminated cultures.
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Fig. 2. Micrographs of left lung lobe segment of mouse infected with moderate-dose of Mtb i.v. (A–C) 24 h and (D–F) 4 weeks after
infection. (A, B) Predominance of PMN and histiocytes (arrows) in the granuloma (150, 500, H&E). (D, E) Predominance of
histiocytes & lymphocytes with very few PMN (150, 500, H&E). (C, F) Mtb Ag (arrows) are localized in the histiocytes. Ag are more
abundant at 4 weeks than at 24 h after infection (500, immunoperoxidase staining with ABC using anti-BCG polyclonal Ab).
inflammatory infiltrate obliterated almost the whole lung
parenchyma. Many degenerating cells were observed. My-
cobacterial Ag, found mainly intracellularly in histiocytes,
were detected in all the lesions by immunoperoxidase stain-
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ning with polyclonal anti-BCG antiserum. The amount of
the Ag increased with the progression of the disease. The
staining pattern was mainly distinctively granular, while
some cells exhibited a more diffuse staining. This pattern
of Ag staining remained rather uniform throughout the
course of infection (Fig. 2C, F).
Mice who received a high-dose of Mtb i.p. developed
gross changes as described above at the 7th week of in-
fection. Microscopically their lungs showed granuloma-
tous changes from the 4th week after infection (similar to
that seen in the i.v. moderate-dose group at the 4th
week). The surrounding lung parenchyma was hypercellu-
lar (Fig. 3A, B). After 8 weeks of infection when the
mice were sick, the inflammatory foci became larger and
more numerous than those in the earlier week of infec-
tion. The cellular composition of these foci was similar to
those in earlier week of infection. Mycobacterial Ag were
found in all the lesions and the staining pattern and dis-
tribution was the same as in the i.v. infected mice. The
amount of Ag was however less in this group compared
to the moderate-dose i.v. group (Fig. 3C, 2F). There were
no obvious histopathological changes in livers and spleens
of mice from this group.
Sub-clinical infection
Mice in group B did not show any signs of disease
throughout the course of infection. In the lungs of mod-
erate-dose i.p. infected mice, the number of CFU gradu-
ally increased until the 21st week of infection. After that
the counts decreased gradually. Between the 21st and
52nd week of infection, the counts appeared stable in the
lungs (Fig. 4A). Higher counts were demonstrated in liv-
ers and spleens compared to lungs during the first 4 week
of infection. In livers, the CFU declined from the 1st
week post-infection, and bacilli were not detected between
the 13th and 36th weeks post-infection (except for 1
mouse at the 52nd week post-infection) (Fig. 4C). In
spleens, the CFU were stable between the 21st and 52nd
weeks of infection (Fig. 4B).
There was no detectable bacillary growth in the lungs
of low-dose i.p. infected mice. Although bacilli were de-
tected regularly in the spleens, low numbers of bacilli
were occasionally cultured from the livers of these mice.
The growth pattern of bacilli in the organs of mice
inoculated with low-dose i.v. followed that of moderate-
dose i.v. infected mice (Fig. 1D, B), but the number of
CFU in their organs was lower than those of moderate-
dose infected mice. They did not show any sings of dis-
ease at the termination of the experiment (15th week
post-infection).
Mice in group B did not show any gross changes in
their lungs, livers and spleens. Microscopically there were
no pathological changes either. Immunohistochemical
staining revealed no mycobacterial Ag.
Fig. 3. Micrographs of left lung lobe segment of mouse, 4 weeks
after infection with high-dose i.p. (A, B) Granuloma shows pre-
dominance of histiocytes and lymphocytes (150, 500, H&E).
(C) Mtb Ag (arrows) are localized in the histiocytes (500,
immunoperoxidase staining with ABC using anti-BCG polyclonal
Ab). Few Mtb Ag-positive cells are found (arrows). Note the
higher number in i.v. route at 4 weeks (Fig. 2F).
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Fig. 4. CFU in organs of moderate doses Mtb infected mice (from
experiment 2): (A) lung, (B) spleen, and (C) liver. ( ) 4104, and
() 4105 Mtb CFU given i.p.; (!) mice started to be sick.
macroscopically greyish-black pinpoint nodules. Micro-
scopically the inflammatory foci were similar to those that
developed during clinical disease as described above (Fig.
5A, B). Mycobacterial Ag were found in all the lesions and
located mainly in the histiocytes. The staining pattern was
mainly granular, but sometimes diffuse as well (Fig. 5C).
The mice developed disease after corticosterone challenge
and showed the above mentioned pathology.
Long term obser6ation on corticosterone non-challenged
mice
56 mice in the low- and moderate-doses i.p. group who
were not given corticosterone treatment stayed healthy
until\100 weeks after infection.
Around week 107, mice in the moderate-dose group
started to show signs of sickness. Macroscopically nodular
lesions were seen in the lungs of 7 mice. In 5 of the sick
mice, lobes of the livers were fused. Tumours in the ovaries
were seen in some mice. In the lung of one mouse there was
a metastatic tumour nodule. Among mice not infected with
Mtb signs of sickness were also observed at this age.
Retroperitoneal tumours were seen in one of the uninfected
control mice and in a BCG infected mouse of the same age.
However the rest of uninfected control mice were still
healthy.
Six sick mice were studied for CFU numbers. At week
107 post-infection, 2 sick mice had approximately 2 log10, 1
log10 and 1 log10 higher Mtb CFU in their lungs, livers and
spleens, respectively (Table II) than the CFU numbers in
those organs during the latent phase (Fig. 4). Inflammatory
foci were seen in the lungs. Mycobacterial Ag in these foci
was much less than in mice with same degree of inflamma-
tion and clinical signs in the group A, and barely visible. At
115th week post-infection, the CFU numbers in the lungs,
livers and spleens of the rest of the sick mice were still
similar to the CFU numbers in those organs during the
stable latency period. Foci of inflammatory cells were seen
in the lungs, but there were no mycobacterial Ag in these
lesions.
DISCUSSION
We have established a mouse model for latent TB. Our
operational definition of TB latency in mice is: stable CFU
counts in lungs and spleens without clinical signs of disease
or obvious pathological changes in lungs over a long period
of time and without spontaneous reactivation of disease.
Persistence of bacilli was proven by reactivation using oral
corticosterone, and by in vitro growth of Mtb from lungs
and spleens.
Studies of murine host responses against Mtb have so far
been focused on acute clinical disease with obvious TB
lesions created with high-dose Mtb inoculation. In our
model, there was a stable number of cultivable bacilli
present in lungs and spleens of moderate-dose i.p. infected
mice 26 weeks post-infection and onwards. The Mtb
Clinical disease during corticosterone challenge
After 53 weeks of infection, half of the remaining group B
mice (low- and moderate-dose groups infected i.p.) were
given oral corticosterone. 15 weeks after the start of corti-
costerone challenge (2 weeks after the start of full-dose
corticosterone (68th week post-infection), the mice devel-
oped signs of disease. The clinical signs, bacillary growth
pattern and histopathological changes in the organs of
these mice were similar to those found in group A mice.
The CFU from lungs of mice infected with a moderate-
dose i.p. remained stable until the mice started to show
signs of disease. By 68 weeks post-infection, the counts had
increased by approximately 1–2 log10, compared to during
the stable period (Fig. 4A). The CFU counts in the livers of
moderate-dose infected mice increased from non-detectable
levels during the stable period. At 11 weeks after full-dose
corticosterone challenge (77 weeks post-infection) the
counts were approximately 1.5 log10 higher than 1 week
after inoculation (Fig. 4C). The CFU in the spleens at 2
weeks after full-dose corticosterone challenge had increased
to a level approximately 1 log10 higher than during the
stable phase (Fig. 4B). The bacillary growth in mice in-
fected with low-dose i.p. followed the same pattern.
After 2 weeks with full dose of corticosterone, lungs of
mice with the highest initial dose of infection showed
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Fig. 5. Micrographs of left lung lobe segment of mouse infected
with moderate-dose of Mtb i.p., challenged with corticosterone and
developed reactivation of latent infection. (A, B) The inflammatory
foci are numerous with predominance of histiocytes, lymphocytes,
degenerating cells and few PMN (150, 500, H&E). (C) Abun-
dant Mtb Ag (arrow) are localized in the histiocytes (500,
immunoperoxidase staining with ABC using anti-BCG polyclonal
Ab).
present in the organs of these mice did not seem to provoke
histopathological lesions of TB. The finding of cultivable
bacilli in healthy infected mice without lesions is in agree-
ment with earlier findings in subclinical Mtb infection in
man (35–37) as well as in mouse (25–27, 38). Opie and
Aronson (35) and Griffith (37) studied the recovery of live
Mtb from the lungs in autopsies of people who had died
from causes other than TB. One interesting finding in Opie
et al.’s experiment was that live Mtb was recovered from
31% and 36%, respectively of grossly normal basal and
apical parts of lungs with old TB lesions by using a guinea
pig inoculation method. These normal looking tissues re-
vealed only a little fibrosis on histopathological examina-
tion (35). These authors (35, 37) have frequently been cited
in the literature for the finding of sterilization of the
necrotic lesions from the primary infection, but their find-
ing that live Mtb is present in normal lung tissue from the
same cases does not seem to have been mentioned since
1938 (36).
A chronic murine TB model was first described by Hart
and Rees (25–27). Presumably due to the very high dose of
inoculum, 80% of their mice died from progressive Mtb
infection before they could be examined (26). In our model
corticosterone unchallenged mice with moderate-dose i.p.
survived more than 100 weeks after inoculation without
increasing bacillary numbers in their organs or showing
clinical signs of disease. We could detect the bacilli in their
organs during latency. This is a prerequisite to explore the
host–parasite interaction in situ. Mice in the latent TB
model established by Brown et al. received low doses
(101–103) of Mtb i.v. The bacillary numbers during the
latent phase in their model were too low compared to our
model (30). McCune et al. provided a latent TB mouse
model, the so-called ‘‘Cornell Model’’ (28, 29). Although in
lungs and spleens, the bacilli fell below detectable levels
after anti-TB treatment, revival of bacilli in these organs
occurred in about one third of cortisone unchallenged
anti-TB treated mice. This was probably because of relapse
due to a too short anti-TB treatment, leaving some few
actively growing bacilli behind. The difference of our model
from the ‘‘Cornell Model’’ is that our mice were not treated
with anti-TB drugs, and a stable state host–parasite inter-
action was established.
The stable CFU counts of bacilli in the latent period in
vivo might be due to a fine balance between host killing
and bacillary multiplication. The increasing bacillary
counts after corticosterone challenge (Fig. 4) could thus
simply be an effect of any reduction in the host’s capacity
to kill Mtb. This hypothesis has been challenged by Hart
and Rees (27). Their results have suggested that when
stable CFU counts were observed in the tissues, Mtb had
rather switched to a vegetative, non-multiplying stage and
survived in a ‘‘dormant’’ state. This was also suggested by
Wayne (39). He noticed that growth of Mtb may adapt to
anaerobic or microaerophilic conditions by transforming
into a non-multiplying stage. Further experiments have
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Table II. CFU numbers in organs of corticosterone challenged and unchallenged 4105 CFU i.p. infected mice
Unchallenged (Log10 CFU) Challenged (Log10 CFU)Weeks after infectionOrgans
4 0*Lungs 58
0* 4.270
5.7 ND†107
4.8 ND†115
58 2.8 0*Livers
ND† 2.970
3.8 ND†107
2.3 ND†115
58 2.8 3Spleens
2.6 4.370
107 3.6 ND†
115 2.8 ND†
* Only one third of lung and liver tissues from 1 mouse in each time point were used for culturing.
† Experiments for challenged mice were terminated at 77 weeks after infection due to mortality of the mice.
indicated that this dormant stage could revert to a multi-
plying stage when the cultures were re-aerated (40–43). In
our model, dormant bacilli seemed to lodge largely in
normal lung tissue, implying that low oxygen tension might
not be the only way to initiate this transformation. A recent
study has given support for a common mechanism for
transforming to a stationary phase of bacteria (44). The
authors found sequence homology between the sigma fac-
tor gene (sigF) of Mtb and sporulation sigma factors (SigF)
from Streptomyces coelicolor and Bacillus subtilis and a
stress–response sigma factor (SigB) from B. subtilis. sigF
mRNA of Mtb was identified during stationary phase of
bacillary growth and when bacilli were exposed to various
stresses. mRNA of sigF was not detected during exponen-
tial-phase of bacillary growth.
We noticed no regular correlation between high Mtb
numbers in the organs and severity of clinical signs of
disease in sick mice (Fig. 4). However the degree of histo-
pathological changes of TB lesions seems to correlate to
severity of clinical signs of disease in our studies. Earlier
investigators (45–49) have also noticed these findings. We
also noticed that a few CFU in cultures from mice with
latent TB started to grow\2 months after inoculation.
Bacillary growth from specimens collected from closed
tuberculous cavities of humans has been detected at periods
varying from 3 to 10 months after inoculating onto the
media (50). This might indicate a prolonged lag phase for
bacilli recovered from a dormant stage.
The choice of mouse, route and dose of Mtb infection
has been shown to be important in establishment of latent
TB infection in mice. We employed an F1 hybrid to reduce
the likelihood of seeing immune defects of a recessive
genetic origin compared to inbred strains. In addition, F1
hybrids are genetically homogenous within the group, are
more resistant to infections and have a longer life-span
(51). We chose to use the F1 hybrid of one strain (C57BL:
6J) carrying the Bcg-susceptible gene (Bcgs) and the other
(DBA2) with Bcg-resistant gene (Bcgr) (52). Airborne infec-
tion is undoubtedly the most relevant route of infection for
mimicking human TB in an animal model. Orme estab-
lished a latent TB model in mice with 5–10 CFU given by
aerosol route (31). It is, however, difficult to obtain com-
plete control over the desired dosage in mice when giving
TB bacilli through the aerosol route (45). It poses a hazard
to the researchers, and it is necessary to have sophisticated
and expensive facilities (53). The results reported here
showed that route of infection can modify the outcome of
infection in mice. Mice infected with moderate-dose i.v.
developed clinical disease and started dying by week 20
after infection, whereas mice infected with same dose i.p.
stayed healthy in spite of high numbers of bacilli in the
lungs and spleens (Fig. 4). Costello et al. also noticed that
Mycobacterium bovis (BCG) growth patterns in organs of
mice could vary with the route of inoculation (54). Differ-
ent routes of inoculation could lead to involvement of
different Ag presenting cells (APC) (55, 56). Very low or
high doses of bacilli in the inoculum can affect the develop-
ment of protective immunity (45) and thus mortality (38,
57). In our experiment no. 1, mice infected with high-dose
i.p. developed clinical disease and started to die in early
phase of infection. On the other hand, mice infected with
low-dose i.v. or i.p. neither suffered from clinical disease
nor did they have identifiable histopathological changes in
the organs, even though lungs and spleens revealed about
1,000–10,000 CFU during early phase of infection. We
therefore assume that moderate-dose by the i.p. route is
suitable for the studying of latent infection in mice because
there are higher numbers of bacilli in the organs through-
out the course of infection compared to those infected with
low-dose i.p.
We conclude that it is possible to establish a stable
asymptomatic infection with moderate-doses (4104–4
105) of virulent Mtb bacilli given i.p. to F1 hybrid mice.
The biological characters of latent Mtb bacilli from our
A mouse model for latent tuberculosisScand J Infect Dis 30 67
model and in vitro Wayne’s model will be explored in the
future. Whether this model will prove to be relevant for
latency of TB infection in humans is presently under inves-
tigation.
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